Vietnam Strengthens Vaccine Manufacturing Localization with France to Enhance Health Security and Economic Growth
Vietnam and France are strengthening their collaboration on vaccine manufacturing localization, a strategic move to establish health security and achieve economic growth targets. French pharmaceutical giant Sanofi and Vietnam's VNVC are partnering on technology transfer and human resource development.
This article requires PRO
This article is outside the free access window or is a special report. PRO unlocks it and the full archive.
Related articles
- Vietnam Fosters Vaccine Manufacturing Localization
Vietnam is promoting technology transfer and human resource development to strengthen domestic vaccine manufacturing capabilities. This is part of a national strategy aimed at healthcare self-sufficiency, improved public healthcare, and international contributions.
- Vietnam to Build Vaccine Plant Worth Over VND2.5 Trillion, Aiming for 2028 Production
Vietnam's VNVC is constructing a vaccine and biological product plant worth over VND2.5 trillion (approximately $100 million USD) in partnership with French pharmaceutical giant Sanofi. Operations are slated to begin by late 2027, with the first production of next-generation vaccines expected in 2028, bolstering Vietnam's self-sufficiency and technological capabilities in pharmaceuticals.